Metformin Crescent

Metformin Hydrochloride, the active ingredient in Metformin Crescent, is a Biguanide presented as an oral tablet for oral use. It lowers elevated blood glucose levels and is indicated for the management of type 2 diabetes mellitus in adult patients. The medication works by decreasing hepatic glucose production and improving peripheral insulin sensitivity, helping to achieve better glycemic control.

GNH USA supplies Metformin Crescent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with reliable quality assurance and regulatory compliance.

Metformin Crescent, a Biguanide oral hypoglycemic, acts on glucose metabolism pathways to improve glycemic control.

- Type 2 diabetes mellitus: reduces fasting and post‑prandial blood glucose levels, aiding long‑term disease management. - Prediabetes (impaired glucose tolerance): delays progression to overt diabetes by improving insulin sensitivity. - Polycystic ovary syndrome: lowers insulin resistance and may help restore ovulatory function. - Gestational diabetes (off‑label): assists in achieving maternal glycemic targets when other therapies are unsuitable.

Metformin Crescent may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools, especially at treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe hypoglycemia: usually when combined with insulin or sulfonylureas. - Hepatic failure: impaired liver function may exacerbate toxicity. - Allergic reactions: rash, pruritus, or angioedema. - Myopathy: muscle pain or weakness in rare cases. - Electrolyte imbalance: especially with prolonged diarrhea.

Before initiating Metformin Crescent, clinicians should evaluate patient-specific risk factors and monitor therapy appropriately.

- Renal function assessment: avoid or adjust dose in patients with impaired creatinine clearance. - Hepatic function monitoring: contraindicated in severe liver disease due to lactic acidosis risk. - Cardiovascular status: use cautiously in heart failure or unstable angina. - Elderly patients: start at lower dose and titrate slowly. - Concomitant alcohol use: limit intake to reduce lactic acidosis risk. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Crescent can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol excess: enhances risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics (loop or thiazide): can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Corticosteroids: may increase blood glucose, requiring dose adjustment.